Anesthesia · Neuromuscular BlockadeRegulatory Approvalregulatorymid-term

Hikma's Sugammadex Sodium ANDA218727 Receives Approval Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 12:31:22 PM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Hikma's approval status for Sugammadex Sodium represents a significant development in the neuromuscular blockade market, potentially altering competitive dynamics. Pharma strategy teams must evaluate the implications of this entry and adapt their market strategies to maintain competitive positioning. Regulatory context from FDA (FDA AP — SUGAMMADEX SODIUM (ORIG)) supports the near-term read. Assessment grounded in 15 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of Hikma's entry into the Sugammadex market and adjust strategies accordingly. The strongest clinical anchor is Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain (ClinicalTrials.gov), sub-indication match (nmus rehab). In nmus rehab, 8 regulatory and 4 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from Teva's Sugammadex Sodium Receives FDA Approval Status (Humanexa Signals) — sub-indication match (nmus rehab); entity match (sugammadex sodium). Secondary pressure from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311). This approval status may position Hikma favorably in the market for neuromuscular blockade reversal agents, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUGAMMADEX SODIUM (ORIG) (FDA). Entity match (hikma); Regulatory pathway relevance (nda). The approval status indicates a positive regulatory pathway for Hikma, but final approval and market launch timelines remain critical to assess.

Key Risks

Elevated medium regulatory exposure for Hikma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Hikma's entry could capture market share from existing players, impacting revenue streams and competitive positioning in the neuromuscular blockade sector.
Portfolio teams should assess the implications of Hikma's entry into the Sugammadex market and adjust strategies accordingly.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval and market launch timeline for Hikma's Sugammadex Sodium.
Timeline shift beyond mid term would change urgency.
Outcome from Teva's Sugammadex Sodium Receives FDA Approval Status would change the regulatory/clinical read.
Outcome from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311) would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source

Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Vibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Teva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartislow relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartislow relevance
Sponsor/company relevance (Novartis)
FDA document
View source

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
PubMedmedium relevance
Sub-indication match (nmus rehab)
FDA document
View source
Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinica
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Targeting lymphotoxin β receptor: from mechanism to precision therapy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
Sugammadex Sodium
competitors in anesthesia

Commercial impact

medium

Hikma's entry could capture market share from existing players, impacting revenue streams and competitive positioning in the neuromuscular blockade sector.

Regulatory impact

medium

The approval status indicates a positive regulatory pathway for Hikma, but final approval and market launch timelines remain critical to assess.

What to watch

Monitor the final approval and market launch timeline for Hikma's Sugammadex Sodium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.